Back to journals
Academic Journal

Neuropsychopharmacology

71 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 71 psychedelic papers Blossom tracks from Neuropsychopharmacology line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does Neuropsychopharmacology carry?

Sourced

Tracked papers by publication year; 13 earlier papers published before 2012. Click a year for the running total.

8papers published in 2017

+167% vs 2016

27 published by 2017

Browse papers→

Don't read as the journal's total output: only the 71 of 71 tracked psychedelic papers from Neuropsychopharmacology with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Neuropsychopharmacology publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
32
Anxiety Disorders
27
Neuroimaging & Brain Measures
22
PTSD
12
Medicinal Chemistry & Drug Development
10
Safety & Risk Management
9
Interpersonal Functioning & Social Connectedness
9
Schizophrenia
9
Other
66

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Neuropsychopharmacology cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

MDMA
19
LSD
19
Psilocybin
18
Ketamine
15
DMT
6
Mescaline
3
2C-X
1
5-MeO-DMT
1
Other
2

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Neuropsychopharmacology has 71 tracked papers indexed in Blossom (1996–2026) from 409 authors, most often covering MDMA, LSD and Psilocybin, across Depressive Disorders, Healthy Volunteers and Anxiety Disorders.

Published Papers

Open Accessindividual

CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder

This secondary analysis of a randomised, placebo-controlled trial found that psilocybin selectively reduced cerebrospinal fluid galanin and noradrenaline in people with major depressive disorder. The results suggest that changes in these two signalling chemicals may be part of psilocybin’s biological effect.

Published
Journal
Neuropsychopharmacology
Authors
Paslawski, W., Doyon, D., Ekman, C. J., Yngwe, H., Mamula, D., Zareba-Paslawska, J., Beckman, M., Xu, Z. Q. D., Hökfelt, T., Tiger, M., Lundberg, J., Svenningsson, P.
Open Accessindividual

Acute and post-acute neurobehavioral responses to lysergic acid diethylamide in healthy subjects: a randomized controlled study

This randomised crossover trial (n=45) in healthy adults found that 100 µg LSD improved motor learning the next day and was linked to lower perceived stress and better cognitive flexibility one week later. It also changed EEG and TMS measures of brain activity, but did not alter BDNF levels.

Published
Journal
Neuropsychopharmacology
Authors
Calder, A. E., Diehl, V. J., Lietz, M. P., Yousefi, P., Friedli, N., Coviello, F., Rouaud, A., Beichmann, K., Eckert, A., Hasler, G.
Open Accessindividual

Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants

This double-blind, randomised, placebo-controlled crossover study (n=24) in healthy adults compared acute effects of 2C-B, MDMA and psilocybin. A 30 mg dose of 2C-B produced effects similar to MDMA and some psychedelic changes, while MDMA caused the strongest cardiovascular stimulation and psilocybin caused more anxiety and unpleasant effects.

Published
Journal
Neuropsychopharmacology
Authors
Arikci, D., Borgulya, J., Straumann, I., Vizeli, P., Luethi, D., Thomann, J., Rudin, D., Vukalovic, I., Eckert, A., Liechti, M. E., Holze, F.
Paywallindividual

Psychedelics produce enduring behavioral effects and functional plasticity through mechanisms independent of structural plasticity

This preclinical rat study (n=24; 8 rats per group) shows that a single dose of psilocybin (1.0 mg/kg) or the selective 5-HT2A receptor agonist 25CN-NBOH (1.5 mg/kg) reduces immobility in the forced-swim test, with effects persisting for at least three months. Electrophysiology of medial prefrontal cortex (mPFC) Layer 5 neurons reveals long-lasting functional, but not structural, plasticity—characterised by changes in resting membrane potential, neuronal firing rates, and excitatory synaptic input. In contrast, dendritic spine density and gene-expression markers related to synaptic structure remain unchanged, indicating enduring functional alterations rather than persistent structural modifications.

Published
Journal
Neuropsychopharmacology
Authors
Kramer, H. M., Hibicke, M., Middleton, J., Jaster, A. M., Kristensen, J. L., Nichols, C. D.
Open Accessindividual

Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials

This combined analysis (n=175) of three double-blind placebo-controlled longitudinal experiments investigated the effects of microdosing psilocybin (0.74 -; 1.71mg) on creativity and found that it increased the originality of their ideas while generating novel applications for ordinary things (divergent thinking). However, it did not increase the number of novel ideas, or their ability to detect features that are common across multiple things (convergent thinking).

Published
Journal
Neuropsychopharmacology
Authors
Prochazkova, L., van Elk, M., Marschall, J., Rifkin, B. D., Fiacchino, D., Fejer, G., Hommel, B., Schoen, N.
Open Accessindividual

Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants

In a randomized, double-blind, placebo-controlled crossover in 23 healthy volunteers, MDA produced longer‑lasting, stronger and more psychedelic‑like subjective and autonomic effects and more adverse reactions than equimolar MDMA. Lys‑MDA acted as a functional slow‑release prodrug that delayed onset and peak effects, whereas Lys‑MDMA did not release MDMA and produced no measurable effects, showing lysine conjugation can alter timing but not necessarily improve tolerability.

Published
Journal
Neuropsychopharmacology
Authors
Straumann, I., Vizeli, P., Avedisian, I., Erne, L., Noorshams, D., Vukalovic, I., Eckert, A., Luethi, D., Rudin, D., Liechti, M. E.

Quick Facts

Papers Indexed
71
h-Index
258
Open Access
No
Publisher
Nature Portfolio
Country
Switzerland
Website
Visit